Ultra high resolution Single Photon Computed Emission Tomography for the molecular imaging of brain disease

Informazioni relative al progetto

BRAINSPECT

ID dell’accordo di sovvenzione: 673306

DOI

10.3030/673306

Progetto chiuso

Data della firma CE 20 Aprile 2015

Data di avvio 1 Maggio 2015

Data di completamento 31 Ottobre 2015

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

Milabs BV
Netherlands

Periodic Reporting for period 1 - BRAINSPECT (Ultra high resolution Single Photon Computed Emission Tomography for the molecular imaging of brain disease)

Periodo di rendicontazione: 2015-05-01 al 2015-10-31

Sintesi del contesto e degli obiettivi generali del progetto

MILabs Molecular Imaging Laboratories BV has researched the marketing and commercial feasibility of G-SPECT as a highly improved imaging modality to reposition SPECT for the use in indications that are currently diagnosed with SPECT, that are currently diagnosed with another imaging modality, or that are under diagnosed in another way. G-SPECT is a molecular imaging device using highly sensitive technology to measure functional changes, in a faster manner or using lower tracer doses, by making use of a proprietary unprecedented collimation, reconstruction and acquisition technology and subsequent image extraction software. G-SPECT’s speed and resolution is far superior over current SPECT.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

This feasibility report comprises an inventory of relevant stakeholders and their willingness to support the market introduction of G-SPECT, the assessment of market opportunities and trends, a description of the unmet needs that currently exist in several disease areas, the opportunities and threats in the market, an analysis of IP and FTO and identification of regulatory and reimbursement demands in different geographical areas with the final aim to confirm the commercial feasibility of G-SPECT and to develop a sound business strategy around that. In addition, as part of BRAINSPECT Phase 1, we have optimised G-SPECT with the scanning of several phantoms to optimise the software for the clinical application of G-SPECT.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Based on the results of this study we have concluded that this product has and is receiving an enormous amount of interest from the field and that it is the opinion of many that G-SPECT can bring a significant contribution to the diagnostic standard of several indications in the fields of neurology, cardiology and oncology. The product has a high commercial viability and a great potential to disrupt the molecular imaging market within the next years. In addition we have created a sound business strategy for the current and future sales and marketing of

The very positive feedback as received from important stakeholders has further strengthened our believe that G-SPECT is a highly innovative and clinically relevant solution to improve treatment approaches by better stratifying patients and by improving the treatment decision making process.

milabs-g-spect-300-dpi.jpg